EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

2 University of Colorado Health Sciences Center, Denver, CO, USA Aim: To investigate the use of intravitreal triamcinolone acetonide (IVTA) for the treatment of diabetic macular oedema (DMO) ...

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

Purpose To analyse the effects of intravitreal dexamethasone implant in patients suffering from diabetic macular oedema (DME) on the basis of their visual and functional response to antivascular ...

Diabetic Macular Edema Overview Diabetic Macular Edema ... causing them to leak fluid and leading to swelling in the macula. This swelling disrupts vision and can result in blurred or distorted ...

Patients with diabetic retinopathy can also develop diabetic macular oedema. Both proliferative diabetic retinopathy and diabetic macular oedema are vision-threatening complications but can remain ...

What are the clinical features or factors that suggest treatment should be switched or stopped for people with diabetic macular oedema? For a short explanation of why the committee made this ...

EYE-103 is under clinical development by Eyebiotech and currently in Phase III for Diabetic Macular Edema. According to GlobalData, Phase III drugs for Diabetic Macular Edema have a 62% phase ...

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...